Post-Marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4).

Trial Profile

Post-Marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4).

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms J-ACT
  • Sponsors Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 13 Feb 2009 Actual patient numbers (58) added as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Actual patient numbers (58) added as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top